Quest Diagnostics Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Quest Diagnostics Bundle
Unlock the diagnostics strategic playbook: concise Business Model Canvas & 3-5 investor insights
Unlock Quest Diagnostics’s strategic playbook with our concise Business Model Canvas overview—three to five key insights on how it creates, delivers, and captures value. Dive deeper: the full Canvas (Word & Excel) gives a section-by-section roadmap for investors, advisors, and founders. Purchase now to access company-specific tactics and financial implications.
Partnerships
Hospital and health system alliances
Quest Diagnostics partners with hospitals and integrated delivery networks to provide reference and esoteric testing, leveraging its national lab network that performs more than 150 million diagnostic tests annually. These alliances expand hospital test menus and offload complex lab work while supplying outreach program management and lab stewardship. Joint quality initiatives with partners focus on faster turnaround times and measurable improvements in clinical outcomes.
Managed care and payer contracts
Quest secures in‑network agreements with national and regional payers, including UnitedHealthcare, Cigna, Anthem and Humana, supporting access across care settings. Favorable reimbursement terms drive test volume and patient affordability, contributing to Quest Diagnostics' 2024 revenue of $10.9 billion. Data-sharing with payers enhances utilization management and supports value‑based care. Contracting aligns with population health initiatives and risk‑bearing arrangements.
Physician groups and clinics
Primary care and specialty practices depend on Quest Diagnostics for routine and advanced diagnostics, supporting millions of outpatient encounters annually; Quest reported approximately $11.8 billion in 2024 revenue. EMR integrations streamline ordering and results delivery, reducing turnaround and order errors. Co-developed clinical pathways with physician groups improve appropriateness and speed to diagnosis. Ongoing education programs update clinicians on new assays and best practices.
Life sciences and IVD manufacturers
Partnerships with life sciences and IVD manufacturers give Quest access to cutting-edge assay and instrument platforms and enable co-development of companion diagnostics and LDT validation, accelerating clinical utility and payer uptake. Supply agreements stabilize reagent availability and pricing, while joint studies hasten regulatory clearances and clinical adoption; the global IVD market was about $92 billion in 2024.
- Access: cutting-edge platforms
- Co-development: companion Dx and LDT validation
- Supply: reagent/consumable stability
- Evidence: joint studies → faster regulatory adoption
Public health, employers, and community programs
Quest collaborates with public health agencies on screening, wellness, and epidemiologic initiatives, leveraging its national lab network to support surveillance and outbreak response.
Employer programs cover occupational testing and preventive care for a client base exceeding 300,000 employers and physician groups, integrating on-site and digital health solutions.
Community outreach—through 2,200+ patient service centers and mobile units—improves access in underserved areas and supports targeted screening drives.
- tests processed annually: ~200 million
- employer/physician clients: >300,000
- patient service centers: 2,200+
- surveillance capacity: hundreds of thousands tests/week
National lab network: ~200M tests, $11B revenue via payer and provider partnerships
Quest partners with hospitals/IDNs for reference/esoteric testing via a national lab network processing ~200 million tests annually, supporting outreach and stewardship. In‑network payer deals (UnitedHealthcare, Cigna, Anthem, Humana) underpin 2024 revenue reported near $10.9–11.8B. Collaborations with providers, IVD firms, public health and 300,000+ employer/physician clients extend access through 2,200+ patient centers.
| Metric | Value |
|---|---|
| Tests processed (ann.) | ~200 million |
| 2024 revenue | $10.9–11.8B |
| Patient centers | 2,200+ |
| Employer/physician clients | >300,000 |
| Global IVD market (2024) | $92B |
What is included in the product
Detailed Word Document
A concise, investor-ready Business Model Canvas for Quest Diagnostics covering customer segments, channels, value propositions, key activities, resources, partnerships, cost structure and revenue streams, with competitive analysis and SWOT-linked insights to support strategy, presentations and funding discussions.
Customizable Excel Spreadsheet
High-level view of Quest Diagnostics' business model highlighting how it relieves pain points—streamlining diagnostic workflows, improving care coordination, reducing turnaround times, and enabling scalable, data-driven insights for clinicians and payers.
Activities
High-throughput clinical testing
Running routine chemistry, hematology, immunoassays and microbiology at scale enables Quest to process roughly 500 million diagnostic tests annually (2024), with standardized protocols delivering consistent quality and predictable turnaround. Automation and lab informatics cut manual error and lower per-test cost, while continuous capacity planning and surge staffing smooth demand spikes.
Advanced genomics and esoteric assays
Performing molecular, genetic, and specialized testing, Quest runs advanced genomics and esoteric assays across a network that processes about 200 million laboratory tests annually; assays are validated and labs maintained under CLIA and CAP accreditation. Robust bioinformatics pipelines translate complex variant and multi-omic data into clinically actionable reports. Ongoing collaboration with clinicians refines interpretation and reporting workflows to improve patient care.
Specimen logistics and operations
Coordinating nationwide phlebotomy, collection and courier networks across Quest Diagnostics’ network of more than 2,200 patient service centers and roughly 200 million annual tests ensures timely sample flow. Cold-chain and chain-of-custody integrity are enforced to protect sample integrity and regulatory compliance. Dynamic routing optimizes speed and cost, while exception management minimizes recollects from insufficient specimens.
Data integration and reporting
Data integration at Quest Diagnostics interfaces with EMRs (Epic, Cerner), patient portals and payer systems to automate orders and results delivery, while ensuring interoperability and HIPAA/NIST-aligned cybersecurity. Reports are clinician-friendly and actionable; analytics support population health programs and quality-measure reporting used by providers and payers.
- EMR/payer integrations
- Interoperability & cybersecurity
- Clinician-ready reports
- Population health analytics
Quality, compliance, and client support
Quality, compliance, and client support at Quest Diagnostics ensure adherence to complex state and federal regulations, backed by proficiency testing and continuous improvement programs that support lab accuracy; in 2024 Quest reported approximately $11.1 billion in revenue and served roughly 150 million patient encounters, reflecting scale that demands rigorous oversight. Technical support spans ordering, billing, and result interpretation while client education and account management sustain satisfaction and retention.
- Compliance: multi-jurisdiction regulatory adherence
- Quality: routine proficiency testing, CI programs
- Support: ordering, billing, interpretation tech help
- Client: education, account management, retention
Processing ~500M tests and generating $11.1B revenue (2024)
Processing ~500 million tests (2024) via standardized chemistry, hematology, immunoassays and microbiology; advanced molecular/genomic assays and bioinformatics for ~200 million specialized tests; nationwide phlebotomy/2,200+ patient service centers with cold-chain logistics; EMR integrations, HIPAA-aligned data security, quality/compliance programs supporting $11.1B revenue and ~150M patient encounters (2024).
| Metric | 2024 |
|---|---|
| Tests processed | ~500M |
| Specialized tests | ~200M |
| Patient service centers | ≈2,200 |
| Revenue | $11.1B |
| Patient encounters | ~150M |
Full Version Awaits
Business Model Canvas
The document you're previewing is the actual Quest Diagnostics Business Model Canvas, not a mockup. When you purchase, you'll receive this same complete, editable file—formatted for immediate use. Download includes Word and Excel versions, ready to present or modify.
Resources
National lab network and facilities
Quest Diagnostics maintains a national lab network with dozens of core and regional laboratories for capacity and redundancy, plus specialized centers for esoteric and genomic testing; facilities are accredited to CLIA and CAP standards, and the geographic spread supports rapid turnaround (often same-day to 24–48 hours in many markets) as of 2024.
Skilled workforce and expertise
Quest Diagnostics leverages a skilled workforce of roughly 50,000 employees — including pathologists, medical technologists, genetic counselors, and data scientists — supporting >150 million tests processed annually. Domain expertise underpins test accuracy and innovation, reflected in continued assay development. Ongoing training programs keep skills current, while customer-facing teams manage clinical relationships and provider partnerships.
IT platforms and data assets
LIS, middleware and secure portals link ordering and results across Quest Diagnostics, supporting over 150 million diagnostic tests annually and longitudinal datasets on tens of millions of patients that fuel insights and R&D. Interoperability with major EMRs, including Epic (leading US hospital EHR), is a commercial differentiator. Robust cybersecurity and HIPAA-compliant controls protect patient privacy and data integrity.
Logistics and phlebotomy network
Quest Diagnostics leverages a nationwide logistics and phlebotomy network—over 2,200 patient service centers plus mobile collection capabilities—to expand access; integrated couriers and routing systems preserve specimen integrity and turnaround times, supporting national payer and provider contracts. Scale drives down per-specimen cost through route density and centralized labs, underpinning contract coverage and margin efficiency.
- Network: >2,200 patient service centers
- Access: mobile phlebotomy nationwide
- Quality: courier/routing systems protect specimens
- Economics: scale lowers per-specimen cost
- Coverage: supports national contracts
Brand, payer access, and contracts
Recognition builds trust with patients and clinicians, supporting Quest Diagnostics' scale (about 500 million lab tests processed and $9.6 billion revenue in FY 2024) and referral patterns. In-network status with major payers drives volume and utilization. Multi-year agreements stabilize revenue while payer relationships open doors for diagnostics and value-based services.
- Brand trust: boosts referrals and clinician partnerships
- Payer access: in-network status drives utilization and revenue
- Contracts: multi-year deals smooth cash flow
- Relationships: enable new service rollouts
Nationwide CLIA/CAP lab: $9.6B, 500M tests
Quest maintains a national CLIA/CAP lab network enabling same‑day to 24–48‑hr turnaround in many markets. Workforce ~50,000 supports ~500 million tests and $9.6B revenue in FY2024. Robust LIS/EMR interoperability (including Epic) and HIPAA-grade cybersecurity enable data insights and R&D. Logistics—>2,200 patient service centers plus mobile phlebotomy and centralized couriers—lowers per-test cost.
| Metric | Value |
|---|---|
| FY2024 revenue | $9.6B |
| Tests processed | ~500M |
| Employees | ~50,000 |
| Patient service centers | >2,200 |
Value Propositions
Comprehensive, reliable testing
Quest Diagnostics offers a broad menu exceeding 3,000 assays in 2024, from routine panels to advanced molecular diagnostics, all within one provider. Its centralized labs deliver high accuracy and consistent quality with many results returned within 24–48 hours, improving clinical workflow. Consolidation reduces fragmentation for clinicians and patients and streamlines data integration. This enhances clinician confidence in decisions and supports measurable care coordination gains.
Convenient access and digital tools
Quest offers convenient access via over 2,000 patient service centers and online scheduling, complemented by portals for results, payments, and test info; the lab processes hundreds of millions of tests annually. EMR-integrated ordering streamlines clinician workflows, and transparent digital results measurably improve patient experience and satisfaction.
Specialized expertise and insights
Specialized expertise combines advanced genomics and esoteric testing for complex cases, backed by Quest Diagnostics processing approximately 500 million tests annually. Expert consultation and detailed interpretive reports translate results into actionable decision support. This improves disease management and supports precision medicine and therapy selection for targeted treatments.
Cost-effective, scalable solutions
Economies of scale at Quest Diagnostics lower unit costs through >450 million tests performed in 2024, driving margin improvements and enabling competitive lab pricing. In-network coverage reduces patient out-of-pocket exposure while utilization management programs curb unnecessary testing and payer spend. Predictable negotiated pricing supports hospital and employer budgeting.
- Scale: >450M tests (2024)
- In-network: lower patient OOP
- Utilization: fewer unnecessary tests
- Pricing: predictable negotiated rates
Population health and prevention
- scale: over 200M tests annually (2024)
- care gaps: analytics-driven risk stratification
- payors/employers: improved outcomes, lower costs
- public health: data-informed surveillance and policy
Lab network: >3,000 assays; >450M tests in 2024; >2,000 patient centers
Quest offers >3,000 assays and centralized labs delivering rapid, accurate results, improving clinical decisions and care coordination. Access via >2,000 patient service centers and EMR-integrated ordering streamlines workflows and patient experience. Scale (>450M tests in 2024) lowers unit costs, enables competitive pricing, and supports population-health analytics for payers and employers.
| Metric | 2024 |
|---|---|
| Tests processed | >450M |
| Assays | >3,000 |
| PSCs | >2,000 |
Customer Relationships
Dedicated account management
Relationship managers serve hospitals, payers, and large practices—providing clinical and operational coordination; Quest Diagnostics reported $11.6 billion in revenue in 2024, reflecting broad institutional reach.
Regular reviews align services with changing clinical needs, protocols, and utilization patterns to optimize care pathways.
Clear issue escalation channels ensure responsiveness, while joint operational and data-driven collaboration drives retention and measurable growth.
Self-service and assisted digital support
Quest Diagnostics leverages MyQuest portals and mobile apps to handle ordering, tracking, and billing, streamlining patient workflows. Knowledge bases and chatbots address common queries while secure messaging links clinicians with lab support. This self-service plus assisted-digital model reduces friction and call volumes across Quest’s network, which serves patients in all 50 states and Puerto Rico.
Clinical consultation services
Clinical consultation services give clinicians direct access to pathologists and genetic counselors, leveraging Quest Diagnostics' network of over 1,900 board-certified physicians and PhDs (2024). They provide guidance on test selection and result interpretation to reduce diagnostic uncertainty. Regular education sessions and accredited CME offerings deepen engagement. These services measurably enhance clinical value delivery by improving test utility and care decisions.
Service-level agreements and KPIs
Service-level agreements specify turnaround time, quality and support KPIs tied to diagnostic accuracy, reporting latency and customer response SLA targets, with transparent dashboards that build trust with providers and payers.
Continuous improvement plans use root-cause analysis and corrective actions to close KPI gaps and align incentives—bonuses or penalty clauses—directly with patient outcome and cost-efficiency metrics.
- Defined TAT, quality, support metrics
- Transparent reporting => trust
- CI plans address gaps
- Incentives aligned with outcomes
Community and wellness outreach
Quest Diagnostics runs community screening programs and health fairs and partners with employers and community groups to expand access; patient education at these events increases test adherence and follow-up, strengthening brand trust and referral volume—in 2024 Quest operated about 2,200 patient service centers supporting outreach.
- Programs: screenings, health fairs
- Partnerships: employers, community groups
- Impact: higher patient adherence
- Benefit: stronger brand and access (2,200 centers in 2024)
Institutional reach: $11.6B, 2,200 centers nationwide
Relationship managers serve hospitals, payers and large practices—Quest Diagnostics reported $11.6 billion revenue in 2024, signaling deep institutional reach. MyQuest self‑service plus assisted‑digital workflows and 2,200 patient service centers (2024) streamline orders, billing and tracking. Over 1,900 board‑certified physicians and PhDs (2024) provide consults; SLAs/KPIs link performance to outcomes.
| Metric | 2024 |
|---|---|
| Revenue | $11.6B |
| Patient service centers | 2,200 |
| Board‑certified clinicians | 1,900+ |
| Geographic reach | 50 states + PR |
Channels
Patient service centers
Quest operates about 2,300 patient service centers nationwide, offering walk-in and scheduled blood draws that serve as a frontline brand touchpoint for patients. These centers support routine and specialized collections, including phlebotomy for complex assays, and feed centralized labs that process hundreds of thousands of specimens daily. Standardized protocols across centers enable consistent specimen quality and lower pre-analytical error rates.
Digital portals and mobile apps
Patient and provider portals and mobile apps enable scheduling, orders, and secure results delivery—Quest’s digital channels handle millions of interactions annually, improving turnaround and transparency. Secure messaging and in-app payments meet HIPAA standards and reduce administrative friction. APIs extend into EHRs and partner platforms, supporting integrations across >2,200 patient service centers. Digital adoption cuts result delivery times and boosts patient satisfaction metrics.
EMR/EHR integrations
Quest Diagnostics integrates with major EHRs such as Epic and Cerner to enable embedded ordering and result delivery within clinician workflows, reducing manual steps and transcription errors. These integrations support clinical decision support and coding workflows and deepen stickiness with practices. According to ONC, 96% of U.S. office-based physicians used an EHR as of 2024, increasing integration reach.
Sales and account teams
Field reps and clinical liaisons engage providers and payers with solution selling for complex accounts, supported by training and onboarding to drive adoption; Quest Diagnostics reported approximately $11.9 billion revenue in 2024 and operates a national network of over 2,200 patient service centers, reinforcing local trust.
- Field reach: clinical liaisons to providers and payers
- Sales: solution selling for complex accounts
- Adoption: structured training and onboarding
- Local trust: >2,200 patient service centers, 2024
Direct-to-consumer programs
- select tests without physician visit
- online purchasing & scheduling
- education guides for responsible use
- expands reach across 50 states; >2,200 centers
Omnichannel diagnostic network - 2,200+ centers, 96% EHR reach, $11.9B
Quest channels combine 2,200+ patient service centers, digital portals/APIs, EHR integrations (Epic/Cerner), field sales, and DTC programs to drive access, speed, and provider stickiness; digital channels handle millions of interactions annually and reduce turnaround. 2024 revenue was ~$11.9B, supporting nationwide logistics and integration reach (ONC: 96% EHR use).
| Channel | Metric |
|---|---|
| Patient service centers | >2,200 |
| Revenue (2024) | $11.9B |
| EHR reach | 96% physicians (ONC 2024) |
| Digital interactions | millions/yr |
| DTC | Available across 50 states (where permitted) |
Customer Segments
Physicians and clinics
Primary care physicians and specialists order routine and specialty tests from Quest, which offers a menu of over 3,000 assays and serves approximately 150 million patients annually; value accrues from breadth, reliability, and EHR integration. High-frequency users produce steady volume and predictable reimbursement patterns. Support needs focus on clinician consultation, interpretation services, and workflow integration tools.
Hospitals and health systems
Hospitals and health systems rely on Quest for reference testing and lab management, processing ≈200 million diagnostic tests annually (2024) and supporting extensive outreach partnerships. These clients have complex needs and stringent SLAs (turnaround, accuracy), creating opportunities for co-branded services and bundled analytics. Integration and scale—EHR connectivity, consolidated lab networks—are critical to reduce costs and meet performance metrics.
Managed care and insurers
Managed care and insurers demand cost-effective, high-quality diagnostics and increasingly use population-health analytics and utilization controls; Quest reported about $11.0B revenue in 2024 and operates ~2,200 patient service centers, enabling broad in-network access. Data sharing and analytics support payers’ shift toward value-based models and reduced utilization costs.
Employers and occupational health
Quest Diagnostics offers wellness screenings, drug testing, and workplace health initiatives that drive productivity and compliance while controlling healthcare and disability-related costs; its national network of 2,200+ patient service centers (2024) supports distributed workforces, and standardized reporting feeds HR and benefits with lab-grade data for population health management.
- Wellness screenings: productivity, early detection
- Drug testing: regulatory compliance, risk reduction
- Health initiatives: lower claim costs, reduced absenteeism
- National coverage: 2,200+ centers (2024)
- Reporting: HR-ready aggregate and individual lab reports
Patients and consumers
Patients seek convenient, affordable testing with fast results and clear explanations; Quest Diagnostics reported about 145 million patient encounters and processes over 500 million tests annually (2024). Direct-to-consumer demand increased in 2024, and privacy plus access (extensive PSC network, HIPAA compliance) remain top priorities.
- Convenience: retail, home-collection
- Speed: same-day/24–48h
- DTC growth: 2024 uptick
- Privacy/access: HIPAA, wide network
>3,000 assays assays•~500M tests•2,200+ PSCs
Primary care, specialists, hospitals, payers and employers rely on Quest for >3,000 assays, ~500M tests and ~145M patient encounters (2024), delivering scale, EHR integration and consultative support. Hospitals use Quest for reference testing with strict SLAs; payers leverage analytics for value-based care. Employers use 2,200+ PSCs for screenings/drug testing; DTC demand rose in 2024.
| Segment | Key metrics (2024) | Primary needs |
|---|---|---|
| Clinicians | >3,000 assays; reliability | EHR integration, consults |
| Hospitals | ≈200M ref tests | Turnaround, SLAs |
| Payers | $11.0B revenue; analytics | Cost control, population health |
| Employers/Patients | 2,200+ PSCs; 145M encounters; 500M tests | Convenience, speed, privacy |
Cost Structure
Labor and clinical staffing
Salaries drive a large share of Quest Diagnostics labor costs: technologists typically range $55,000–80,000, pathologists $300,000–500,000 and support staff $40,000–80,000 (2024 market ranges). Ongoing training and retention add roughly 1–3% of payroll annually. Labor costs scale with test volume and case complexity, with overtime and rotating shifts used to cover peak demand.
Reagents, consumables, and equipment
Assay kits, consumables and instrument depreciation are major line items for Quest Diagnostics, with specialized molecular and genetic tests carrying materially higher per-test input costs. Vendor contracts and volume-based pricing negotiated in 2024 materially influence margins. Quest processed roughly 200 million diagnostic tests in 2024, making inventory management and lean stocking critical to reduce waste and obsolescence. Efficient supply chain execution therefore directly protects EBIT.
Logistics and facility operations
Couriers, fuel, and fleet maintenance drive variable costs across Quest Diagnostics’ network, which supports more than 2,200 patient service centers and a national logistics fleet; fuel price swings directly impact per-sample pickup costs. Utilities, facility leases, and maintenance for labs and PSCs are significant fixed and semi-fixed expenses tied to capacity and hours of operation. Cold-chain packaging and refrigerated transport preserve specimen integrity and add specialized supply and energy costs. Route optimization and consolidation efforts have been used to lower miles driven and reduce spend against a roughly $11.0 billion revenue base in 2024.
IT, integrations, and cybersecurity
IT, integrations, and cybersecurity costs at Quest Diagnostics center on licensing, infrastructure, and ongoing LIS and patient portal development, plus interface build/maintenance with EMRs and payers; these drive recurring license and cloud hosting spend. Significant investment goes to data protection and compliance (HIPAA/SOC 2) and analytics platforms that enable actionable lab insights and population health reporting.
- Licensing & cloud
- EMR/payer interfaces
- Security & compliance
- Analytics platforms
Sales, marketing, and compliance
Sales, marketing, and compliance costs at Quest Diagnostics fund account teams, client onboarding and support, education, and promotional activities while covering regulatory, accreditation, and legal expenses; quality programs and proficiency testing are maintained to meet CLIA and CAP standards. Quest Diagnostics (NYSE: DGX) reported full-year 2024 revenue of $11.8 billion, supporting these SG&A and compliance investments.
- Account teams, onboarding, support
- Education, promotional activities
- Regulatory, accreditation, legal
- Quality programs, proficiency testing
Labor and consumables pressure margins: $11.8B, ~200M
Salaries (technologists $55k–80k, pathologists $300k–500k, support $40k–80k) and training drive largest operating costs, scaling with ~200M tests processed in 2024. Consumables, assay instruments and vendor pricing materially affect margins; inventory control reduces waste. Logistics, facilities, IT/security and compliance add fixed/semi-fixed costs across ~2,200 PSCs; 2024 revenue $11.8B.
| Metric | 2024 |
|---|---|
| Revenue | $11.8B |
| Tests | ~200M |
| Patient Service Centers | ~2,200 |
Revenue Streams
Fee-for-service test revenue
Fee-for-service test revenue at Quest Diagnostics comprises payments from payers, providers, and patients per test and was the primary contributor to Quest’s reported 2024 revenue of $9.9 billion. This stream drives both routine and specialty assays, with pricing varying by payer contract and test complexity. Total receipts are highly sensitive to testing volume and mix, where higher specialty-test mix commands materially higher per-test revenues.
Capitated and value-based contracts
Capitated and value-based contracts with payers shift Quest Diagnostics to per-member/outcome-linked payments, aligning incentives for efficiency and quality; in 2024 Quest reported about $11.1 billion in revenue, funding the robust analytics and utilization controls needed to manage risk and measure outcomes, and supporting population health goals through preventive, high‑value testing and care coordination.
Reference and esoteric testing
Reference and esoteric testing deliver high-margin, complex assays for hospitals and labs—specialized genetics, oncology, and infectious disease panels that trade lower volume for higher price points and expertise-driven differentiation; the global esoteric testing market was valued at about $20.9 billion in 2024, underscoring premium pricing and strong margin contribution.
Employer and occupational programs
Employer and occupational programs deliver bundled screenings, wellness panels and DOT/non-DOT drug testing packages under contracted pricing for large groups; Quest Diagnostics reported total 2024 revenue of $11.3 billion, with employer solutions contributing a high-margin, recurring portion of corporate and occupational services.
- Contracted pricing for large groups
- Seasonal/event-driven testing surges
- Wellness panels + drug testing packages
- Reporting and analytics add service value
Direct-to-consumer testing
$11.1B testing revenue; 150M patients grow cash & value
Fee-for-service testing remained Quest Diagnostics’ core revenue driver within reported 2024 total revenue of $11.1 billion. Esoteric and specialty assays delivered higher margins and strategic differentiation. Employer/occupational, capitated/value-based contracts and direct-to-consumer cash-pay sales diversified recurring and cash revenue while expanding the 150 million patients served annually.
| Metric | 2024 |
|---|---|
| Total revenue | $11.1 billion |
| Patients served | 150 million |